{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2691549"],"location":["China"],"study_start_month":["3"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"The safety, tolerability and preliminary efficacy of pd-l1 monoclonal antibody combined with lenalidomide in third-line post-treatment of patients with microsatellite stable advanced colorectal cancer: a phase I clinical stud","description":"Interventions: single arm:Pd-l1 monoclonal antibody and lenalidomide\nPrimary outcome(s): Security;Tolerance\nStudy Design: Single arm","dates":{"creation":"2020-03-15"},"accession":"2691549","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2000030847"]}}